NCT06037525

Brief Summary

Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular diseases

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2018

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 13, 2020

Completed
2.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

June 1, 2023

Completed
4 months until next milestone

First Posted

Study publicly available on registry

September 14, 2023

Completed
Last Updated

November 18, 2023

Status Verified

November 1, 2023

Enrollment Period

2.9 years

First QC Date

June 1, 2023

Last Update Submit

November 16, 2023

Conditions

PainCatheter Infection

Outcome Measures

Primary Outcomes (1)

  • Dwelling Time

    Length of catheter in situ time

    0-29 days

Secondary Outcomes (2)

  • Administration of Alprostadil

    0-29 days

  • Catheter Complications

    0-29 days

Interventions

PowerGlide™ Pro Midline CatheterDEVICE

Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular disease

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients in the vascular surgery department with above mentioned inclusion criteria

You may qualify if:

  • need for i.v. therapy longer than 7 days
  • poor peripheral vein status
  • Administration of alprostadil

You may not qualify if:

  • pending dialysis
  • allergy to catheter material
  • minor age
  • life threatening conditions
  • requirement for central venous catheter

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Augsburg

Augsburg, 86165, Germany

Location

MeSH Terms

Conditions

Pain

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Alexander Hyhlik-Duerr, PhD

    University Hospital Augsburg Vascular Surgery

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 1, 2023

First Posted

September 14, 2023

Study Start

January 1, 2018

Primary Completion

November 13, 2020

Study Completion

May 1, 2023

Last Updated

November 18, 2023

Record last verified: 2023-11

Locations

DE(1)